Jubilant Pharmova LtdNSE: JUBLPHARMA
Open the Jubilant Pharmova Ltd page
Follow Jubilant Pharmova LtdFree account. Get a note when Jubilant Pharmova Ltd files.
Q2 FY27 earnings call · November 16, 2026

Jubilant Pharmova Q2 FY27 Earnings Call: Revenue Up 21%, Guides Mid-Teens H2 Margins (JUBLPHARMA)

Cofacto ResearchPublished November 16, 20268 min read
Listen to the earnings call
Quick summary

Jubilant Pharmova Ltd held its Q2 FY27 earnings call on November 13, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Top Line, Compressed Margins

  • Q2 FY 2026-2027 revenue up 21% YoY to Rs.2,370 crore — growth across CDMO sterile injectables, allergy, radiopharma and generics; EBITDA of Rs.255 crore and PAT of Rs.31 crore.
  • H1 FY 2026-2027 revenue grew 19% to Rs.4,599 crore — with EBITDA of Rs.523 crore and PAT of Rs.87 crore.
  • EBITDA margins declined YoY in both Q2 and H1 FY 2026-2027 — management attributed this to unavailability of high-margin spec radiopharma products, negligible third-party revenues, higher operating expenses, and incremental remediation costs at the CDMO Montreal facility.
  • Rs.800 crore of non-convertible debentures raised — successfully completed during the quarter.
  • H2 FY 2026-2027 outlook — management expects revenue growth momentum to continue and margins to improve quarter on quarter, with H2 FY 2026-2027 average margins in the mid-teens.

The Margin Drag and the Path Back

  • Montreal facility lost more than Rs.80 crore in Q2 FY 2026-2027 — covering remediation costs and OpEx, with no third-party revenue coming in; H1 FY 2026-2027 losses were about Rs.157 crore, after about Rs.200 crore before that, on a cumulative basis.
  • Remediation costs should decrease — Harshav Singh said costs should fall by "substantially... more than low double digits, Q over Q" (period unspecified), with quarter-over-quarter improvements in spend at Montreal expected.
  • Radiopharma margins fell from 40% to 32% over the last four quarters — per Nuvama analyst Shrikant Akolkar; CFO Mukirwar guided spec supply to normalize, particularly in Q4 FY 2026-2027, moving the radiopharma margin back toward 40%.
  • RUBY-FILL margins are currently below the overall radiopharma margin — so as RUBY-FILL's contribution rises due to unavailable Montreal spec products, the overall radiopharma margin falls; management declined to give product-level margins.
  • SPECT margin structure expected roughly stable in FY 2027-2028 — with declining tech-transfer OpEx as Montreal is de-risked; two significant radiopharma launches are planned for the back half of 2028, expected to be margin-accretive but with associated SG&A.
  • Montreal H2 FY 2026-2027 burn should be lower than H1 — with spec production expected to help absorb costs and remediation costs declining as production normalizes into FY 2027-2028; the company is past the 90-day threshold after the Montreal warning letter.

Line 3 Ramp, Line 4 Pipeline Building

  • Line 3 generated about $20 million of revenue in Q2 FY 2026-2027 — from 13+ tech transfer projects and 5+ customers; double-digit revenue growth expected in H2 FY 2026-2027 and FY 2027-2028, driven by demand for US isolator capacity amid geopolitical uncertainty and market consolidation.
  • Line 3 peak revenue attainment is expected 1.5 to 2 years later than original McKinsey modeling projections — management still holds to its full-year utilization projection of $80-90 million, with line 3 close to full utilization in FY 2027-2028.
  • Line 4 build-out is complete and media fills were completed in Q2 FY 2026-2027 — a major qualification step; tech transfers for "a project or two" are on track to start by Q4 FY 2026-2027, with more customers expected to sign and tech transfer work continuing into FY 2027-2028.
  • 23 active proposals for line 4 capacity buys — Chris Preti cited a book of business and RFPs at its "strongest point ever," plus 51 live customer meetings at the CPHI international manufacturing meeting about three weeks before the call.
  • Line 4 peak revenue attainment of 80 to 90 million projected within 1.5 to 2 years — the same timeline as line 3, applying line 3 learnings (five-plus customers and 13 projects) to line 4 qualification and product approval.
  • CDMO margins under pressure until line 3 costs are fully absorbed — CFO Mukirwar said tech transfer carries higher labor costs and lower margins, with gradual improvement in FY 2027-2028 and significant margin improvement expected in FY 2028-2029; line 4 margin dilution guidance deferred to H2 FY 2026-2027.
  • Spokane facility received VAI status and line 3 secured first product approval without a pre-approval inspection — cited by Preti as signs of the high quality bar customers demand; a master services agreement was signed with a large pharma customer for one of its largest global oncology products.

RUBY-FILL Expansion, PET Rollout, MIBG Filing

  • RUBY-FILL growth tracking about 35% YoY — with Q2 FY 2026-2027 at 30% annualized; the FY 2026-2027 absolute growth run rate is higher than FY 2025-2026, and margins improved in Q2 FY 2026-2027.
  • $67 million of capex announced to double manufacturing capacity — supporting RUBY-FILL growth, with capex of CAD 94.5 million; the Government of Canada agreed to provide support of CAD 23.8 million for the Ruby-Fill capex.
  • New RUBY-FILL capacity expected online in the back half of FY 2029 — management expects efficient utilization to generate a return on capital of more than 20% on the investment (period unspecified).
  • Cyclotrons deployed at 5 of 6 new PET sites — with 1 more coming shortly; 3 sites in final qualification, 2 mid-qualification, and 1 cyclotron being delivered; the first new PET site is expected online in Q3 FY 2028, with 2-3 sites starting that quarter and the remaining 3 over the next 2 quarters.
  • Distribution contract signed with one of the largest PET providers in the category — which has submitted volume deliverables, with tech transfer packages starting now; the new sites are FDA GMP sites, and because products are radioactive, filing can follow quickly after tech transfer batches.
  • MIBG NDA on track to file in "Q4 of 2027" — or very early the following quarter; the Optimum pivotal registration trial is completed and closed, with blinded independent review progressing well.
  • PET CMO economics are stronger than pharmacy — Harshav Singh said cyclotrons are "substantially more profitable" than specialty pharmacy sites and "significantly EBITDA positive" individually and at network level; management declined to give segment-level revenue or EBITDA margin guidance for a mature PET site.

Launch Momentum vs API Pricing Pressure

  • 13 ANDA approvals secured since April 2024 — when the previous USFDA inspection closed with VAI; the company is monetizing these launches, plus in-licensing fully packaged products and doing site transfers away from Rudki to avoid concentrating products in one site.
  • 6 to 8 product launches per year guided for FY 2026-2027 — targeting products with lower competition, not necessarily complex or differentiated ones; generics margins expected to improve on new launches planned for Q3 FY 2026-2027 and Q4 FY 2026-2027.
  • Generics EBITDA margin range of 15-17% reaffirmed — from the vision laid out in February 2025; Jaydev Rajpal said trailing twelve months and FY 2025-2026 are moving in that direction, and did not endorse the analyst's suggested 25-30% margin at roughly Rs.1,000 crore scale.
  • API business at 2% in Q2 FY 2026-2027 — per Nuvama's Shrikant Akolkar, who noted API has declined since Q3 FY 2025-2026 and described the quarter as stable; CFO Mukirwar said API pricing pressure continues given the geopolitical scenario, with API expected to stay stable at the current run rate if conditions persist.
  • FY 2027-2028 should be better for API if sovereign prices improve — per CFO Mukirwar, who will provide API guidance when the company enters the new year.
  • Discovery ramp-up expected to continue significantly in FY 2027-2028 — with green shoots from Q4 FY 2026-2027; win rate is "much better than the industry," and Vision 2030 discovery targets continue to stand, though Mukirwar declined to confirm double-digit CC growth for FY 2027-2028.
  • API custom manufacturing additive at Nanjangud — already serving one customer for an off-patent API and in discussions with one more big pharma; commercialization could happen sooner than the analyst's FY 2028-2029 estimate depending on the product.

Peak Capex Year, Deleveraging Toward FY30

  • FY 2026-2027 capex guided at around Rs.1,800-1,900 crore — the company's highest capex cycle, covering RUBY-FILL new capacity, Line 4 and PET installation; capex expected to fall substantially to around Rs.1,000 crore in FY 2027-2028.
  • Net debt guided closer to Rs.4,000 crores by end of FY 2026-2027 — per CFO Mukirwar; for FY 2027-2028, capex will be significantly lower and, if things go as planned, net debt is not expected to rise above the end-FY 2026-2027 level.
  • Net debt zero by end of FY30 vision maintained — responding to Shashank Rastogi citing debt-to-EBITDA of 2.2x in Q2 FY 2026-2027, Mukirwar said the company is "maintaining its vision of net debt zero by end of FY30," with FY29 and FY30 expected to be significantly cash-generating years.
  • EBITDA margins and cash flows should improve starting FY 2027-2028 — driven by new radiopharma launches, new PET pharmacies starting FY 2027-2028, and lines three and four reaching commercialized revenue starting FY28.
  • JBI-802 in Phase 1/2 with 12 to 17 patients enrolled — management believes it is best in class based on initial data while noting Besremi (USFDA-approved in the same indication about three months earlier) carries a black box warning, but called this belief speculative; the company wants to complete the trial on its own before evaluating monetization, fundraising or out-licensing, with all options open.
  • FY 2027-2028 guidance deferred — Harshav Singh said guidance will come on the next call and it is too early to guide now; management expects significant progress on new radiopharma products planned for launch in FY28 and FY29.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.